Seven Silent Signs of Ovarian Cancer Often Mistaken for Aging

Ovarian cancer moves through the body like a thief in the night. By the time most women discover it, the disease has already spread—roughly seven out of every ten diagnoses arrive at advanced stages, when treatment options narrow and survival becomes harder to guarantee. The silence of this particular cancer is what makes it so dangerous. Its symptoms wear the disguise of ordinary aging, of digestive trouble, of hormonal shifts that women over fifty have learned to expect and accept as the price of growing older.

Brazil will see approximately eight thousand new cases of ovarian cancer each year through 2028, according to current projections. That number matters more than it might seem, because the country's population is aging faster than most. By 2070, nearly four in ten Brazilians will be sixty or older—almost triple the proportion today. As the population grays, so too will the incidence of diseases tied to age, ovarian cancer among them. The math is grim: more older women means more cases, and more cases means more deaths unless diagnosis happens earlier.

The problem is that early warning signs refuse to announce themselves clearly. A woman might notice her belly feels perpetually swollen, even though she hasn't changed what she eats. She might feel full after eating just a small amount of food, her stomach signaling satiety that seems out of proportion to what she consumed. Pain might settle into her pelvis, her abdomen, her lower back—the kind of ache that could mean almost anything. Her bowels might behave strangely: constipation one week, gas the next, a general sense that something inside has shifted. Her weight might drop without explanation, no diet, no new exercise routine, just a gradual thinning. Her belly might grow rounder even as the rest of her shrinks. All of these things can point to ovarian cancer. All of them can also point to menopause, to aging, to digestive issues, to a dozen other conditions that feel far less frightening.

Cristovam Scapulatempo Neto, a medical director of pathology and genetics at Delboni, part of the Dasa network, explains the core challenge: the initial signals are frustratingly nonspecific, easily confused with hormonal changes, intestinal problems, or the simple wear of getting older. Women normalize these symptoms. They tell themselves this is what fifty or sixty or seventy feels like. They delay seeking medical evaluation, sometimes for months or years, because nothing feels urgent enough to warrant a doctor's visit. Meanwhile, the cancer deepens its hold.

The ovaries sit deep within the pelvis, tucked away where tumors can grow quietly, almost invisibly. A gynecologist named Adriana Bittencourt Campaner notes that many patients convince themselves they're dealing with digestive issues or hormonal fluctuations, not realizing that what they're experiencing might be something far more serious. By the time they arrive at a doctor's office, the disease has often progressed beyond the point where early intervention could have made a difference.

Unlike breast cancer or cervical cancer, ovarian cancer has no reliable screening method for the general population. There is no simple test that catches it early, no standard protocol that works across the board. What exists instead is the necessity of regular gynecological care and individualized investigation—ultrasound imaging through the vaginal wall, magnetic resonance imaging, genetic testing for those with a family history of cancer. The last of these has become increasingly important. Women whose mothers, sisters, or grandmothers developed breast or ovarian cancer carry elevated risk, especially if they carry mutations in the BRCA1 or BRCA2 genes, inherited variations that dramatically increase the likelihood of disease.

Precision medicine is beginning to change the landscape. Genetic testing can now identify these hereditary mutations, allowing doctors to tailor treatment to the specific molecular signature of each tumor. PARP inhibitors—drugs that work by targeting cells with deficient homologous recombination repair—have emerged as a powerful tool for patients carrying BRCA mutations. These therapies represent a shift toward personalized oncology, toward matching the drug to the disease rather than applying a one-size-fits-all approach. Scapulatempo Neto emphasizes that modern cancer care increasingly moves in this direction: identifying specific molecular alterations expands therapeutic possibilities and can improve clinical outcomes.

But these advances matter only if women reach diagnosis while treatment still has teeth. The silence of ovarian cancer remains its most lethal feature—not the disease itself, but the delay that silence creates. A woman who learns to listen to her body, who refuses to dismiss persistent symptoms as merely the sound of aging, who insists on investigation when something feels wrong: she gives herself the best chance that medicine currently offers.